PJSC “farmsintez” company from South Korea THELMA Therapeutics Co.,Ltd. signed an agreement to develop a new and improved version of oxidehydrogenation for the prevention and treatment of COVID-19. The updated product will be delivered to the world markets together with the project partners. The rights to the original drug (trade name Neovir) remain at PJSC “pharmsynthez”, the terms of this agreement do not apply to him, reported the press service of the company.
Oxidehydrogenation is an original Russian drug intended for the treatment of prevention of diseases caused by DNA – and RNA-containing viruses, including coronaviruses. This drug is included in the list of drugs recommended by the MoH for the treatment and prevention of influenza. The drug is also indicated in the temporary methodical recommendations “Drug therapy of acute respiratory viral infections (ARVI) in the outpatient practice during the epidemic СOVID-19”.
In accordance with the terms of the agreement, the creation of a new drug will be held in several stages and will take at least one year. For their implementation PJSC “farmsintez” will provide the necessary means for the conduct of clinical studies the batch of the medicinal product and production know-how, while THELMA Therapeutics will begin preclinical and clinical trials. If successful, the Korean company plans to supply medicine to countries around the world by sharing with PJSC “pharmsynthez” ownership of the patents for treatment COVID-19.